HADDE71 polypeptides

• US 7,368,527 B2
• Filed: 03/26/2002
• Issued: 05/06/2008
• Est. Priority Date: 03/12/1999
• Status: Expired due to Fees

• Current Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Original Assignee: Human Genome Sciences Incorporated (GlaxoSmithKline PLC)
• Inventors: Rosen, Craig A., Ruben, Steven M.
• Primary Examiner(s): McKelvey; Terry
• Application Number:
  US10/105,299
• Publication Number:
  US 20070032413A1
• Time in Patent Office: 2,233 Days
• Field of Search: 530/300, 530/325, 530/350
• US Class Current: 530/300
• CPC Class Codes: A61K 38/17 from animals; from humans enzyme inhibitors A61K38/005
• CPC Class Codes: C07K 14/47 from mammals
• CPC Class Codes: G01N 2500/00 Screening for compounds of potential therapeutic value
• CPC Class Codes: G01N 33/566 using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating diseases, disorders, and/or conditions related to said human secreted proteins. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.

Claims

1. An isolated polypeptide comprising amino acid residues 29 to 139 of SEQ ID NO:

3118.

2. The isolated polypeptide of claim 1 which comprises amino acid residues 2 to 139 of SEQ ID NO:

3118.

3. The isolated polypeptide of claim 1 which comprises amino acid residues 1 to 139 of SEQ ID NO:

3118.

4. The polypeptide of claim 1 which further comprises a heterologous polypeptide sequence.

5. A composition comprising the polypeptide of claim 1 and a carrier.

6. An isolated protein produced by the method comprising:

(a) expressing the polypeptide of claim 1 by a cell; and

(b) recovering said protein.

7. An isolated polypeptide comprising the amino acid sequence of the secreted portion of the polypeptide encoded by the HADDE71 cDNA contained in ATCC Deposit No. 203917.

8. The isolated polypeptide of claim 7 which comprises the amino acid sequence of the complete polypeptide encoded by the HADDE71 cDNA contained in ATCC Deposit No. 203917, excepting the N-terminal methionine.

9. The isolated polypeptide of claim 7 which comprises the amino acid sequence of the complete polypeptide encoded by the HADDE71 cDNA contained in ATCC Deposit No. 203917.

10. The polypeptide of claim 7 which further comprises a heterologous polypeptide sequence.

11. A composition comprising the polypeptide of claim 7 and a carrier.

12. An isolated protein produced by the method comprising:

(a) expressing the protein of claim 7 by a cell; and

(b) recovering said protein.

13. An isolated polypeptide consisting of at least 30 contiguous amino acid residues of amino acid residues 1 to 139 of SEQ ID:

3118, wherein said polypeptide comprises amino acid residues 1-20, 21-40, 41-60, 61-80, or 81-100 of SEQ ID;

3118.

14. The polypeptide of claim 13 which further comprises a heterologous polypeptide sequence.

15. A composition comprising the polypeptide of claim 13 and a carrier.

16. An isolated protein produced by the method comprising:

(a) expressing the polypeptide of claim 13 by a cell; and

(b) recovering said protein.

17. An isolated polypeptide consisting of at least 30 contiguous amino acid residues of the complete polypeptide encoded by the HADDE71 cDNA clone in ATCC Deposit No. 203917, wherein said polypeptide comprises amino acid residues 1-20, 21-40, 41-60, 61-80, or 81-100 of the HADDE71 cDNA clone in ATCC Deposit No. 203917.

18. The polypeptide of claim 17 which further comprises a heterologous polypeptide sequence.

19. A composition comprising the polypeptide of claim 17 and a carrier.

20. An isolated protein produced by the method comprising:

(a) expressing the polypeptide of claim 17 by a cell; and

(b) recovering said protein.